Tag: Lutonix
“If we are going to use these devices, we have to...
Delivering first-release data, Scott O Trerotola (University of Pennsylvania, Philadelphia, USA) conveyed the “consistent results” in a real-world environment for the Lutonix arteriovenous (AV)...
Chocolate Touch drug-coated angioplasty balloon for treatment of peripheral artery disease...
Genesis MedTech Group announced that the US Food and Drug Administration (FDA) has approved the Chocolate Touch drug-coated balloon (DCB) percutaneous transluminal angioplasty (PTA)...
Case report: Recanalisation of a long SFA occlusion with Ultrascore™ Focused...
This advertorial, sponsored by BD, is intended for healthcare professionals in Europe only.
“Improving vessel compliance with focused force longitudinal plaque fracture seems to be...
FDA advisory panel recommends against premarket approval of Lutonix 014 DCB...
A US Food and Drug Administration (FDA) advisory panel has recommended against premarket approval of BD’s Lutonix 014 drug-coated balloon (DCB) for use in...
Independent analysis, with oncology input, re-examines DCB data after paclitaxel mortality...
Kenneth Ouriel (New York, USA) talks to BLearning Peripheral at LINC 2020 (Leipzig Interventional Course; 28–31 January 2020, Leipzig, Germany) about a recent independent analysis to assess safety...
LINC 2020: BD announces long-term safety data for BTK drug-coated balloon
Today at the 2020 Leipzig Interventional Course (LINC; 28–31 January, Leipzig, Germany), BD announced that interim findings from the Lutonix below-the-knee (BTK) investigational...
BD announces publication of drug-coated balloon safety data for femoropopliteal PAD
BD has announced the publication of a company-initiated, independent analysis of the Lutonix 035 drug-coated balloon (DCB) femoropopliteal clinical programme in the Journal of...
FDA notifies BD that Lutonix paclitaxel balloon PMA application for below...
The US Food and Drug Administration (FDA) have denied BD premarket approval (PMA) for the company’s Lutonix drug-coated balloon (DCB) in the treatment of...
BD receives FDA approval for expansion to drug-coated balloon product line
The US Food and Drug Administration (FDA) has approved expanded sizes of the Lutonix 018 drug-coated balloon (DCB) to treat long superficial femoral artery...
BD’s Lutonix 018 DCB approved by FDA to treat SFA disease
The FDA has granted approval for BD’s 0.018-inch guidewire-compatible Lutonix 018 drug-coated balloon (DCB) for the treatment of long superficial femoral artery lesions in...
CASE REPORT: SFA-CTO Recanalization by using the novel 0.035″ ULTRASCORE Focused...
This case report is sponsored by BD.
Ralf Langhoff, chief, Angiology/Vascular Medicine, Sankt Gertrauden-Krankenhaus, Berlin, Germany, reports on a case in which his team used...
Lutonix BTK randomised trial meets safety and efficacy endpoints at six...
Six-month outcomes of a multicentre randomised controlled trial using the Lutonix 014 drug-coated balloon (BD; DCB) has demonstrated the DCB is safe to use...
Interim results of the Lutonix drug-coated balloon in a complex patient...
This article is sponsored by BD.
In a complex patient population with advanced, symptomatic below-the-knee peripheral artery disease, treatment with the Lutonix drug-coated balloon (BD)...
Lutonix Global AV Registry: DCB use prolongs time to reintervention in...
Tobias Steinke (Dusseldorf, Germany) reported on the Lutonix Global arteriovenous (AV) Registry at CIRSE 2018 in Lisbon, Portugal. Lutonix Global AV Registry data add to...
Latest data on Lutonix and IN.PACT drug-coated balloons in AV access...
There in an increasing physician interest in exploring the role of drug-coated balloons in arteriovenous (AV) access. At the Leipzig Interventional Course (LINC; 30...
BD announces completion of enrolment in Lutonix 014 DCB below-the-knee trial
Enrolment is complete in the Lutonix below-the-knee trial with BD planning to submit a pre-market approval application to the US Food and Drug Administration...
Bard gets US FDA premarket approval for Lutonix 035 DCB in...
Bard’s Lutonix 035 drug-coated balloon PTA catheter (DCB) has been granted premarket approval (PMA) by the US Food and Drug Administration (FDA) for a...
Lutonix registry data confirm durability of drug-coated balloon treatment in superficial...
The 24-month results of the worldwide experience with Lutonix 035 drug-coated balloon (CR Bard/Beckton Dickenson) were published online in August in JACC: Cardiovascular Interventions....
Lutonix AV results provide tailwind for drug-coated balloons in dysfunctional arteriovenous...
Scott Trerotola presented the first release of eight-month data from the Lutonix AV IDE trial at the Leipzig Interventional Course (LINC; 24–27 January, Leipzig,...
Lutonix Global Real-World Registry 24-month outcomes presented at VIVA 2016
Bard has announced the presentation of the final 24-month results from the Lutonix Global Real-World Registry at the Vascular Intervention Advances (VIVA) 2016 meeting...
